JP2024500698A - クラスｉｉ心不全を有する対象における進行性心不全を治療する方法 - Google Patents

クラスｉｉ心不全を有する対象における進行性心不全を治療する方法 Download PDF

Info

Publication number
JP2024500698A
JP2024500698A JP2023536167A JP2023536167A JP2024500698A JP 2024500698 A JP2024500698 A JP 2024500698A JP 2023536167 A JP2023536167 A JP 2023536167A JP 2023536167 A JP2023536167 A JP 2023536167A JP 2024500698 A JP2024500698 A JP 2024500698A
Authority
JP
Japan
Prior art keywords
subject
cells
heart failure
class
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023536167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500698A5 (enExample
Inventor
シルヴィウ・イテスク
ケネス・ボロウ
ジャック・ヘイズ
Original Assignee
メゾブラスト・インターナショナル・エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904675A external-priority patent/AU2020904675A0/en
Application filed by メゾブラスト・インターナショナル・エスアーエールエル filed Critical メゾブラスト・インターナショナル・エスアーエールエル
Publication of JP2024500698A publication Critical patent/JP2024500698A/ja
Publication of JP2024500698A5 publication Critical patent/JP2024500698A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023536167A 2020-12-15 2021-12-15 クラスｉｉ心不全を有する対象における進行性心不全を治療する方法 Pending JP2024500698A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
AU2020904675A AU2020904675A0 (en) 2020-12-15 Method of treating progressive heart failure in subjects with Class II heart failure
AU2020904675 2020-12-15
AU2021900059A AU2021900059A0 (en) 2021-01-12 Method of treating progressive heart failure in subjects with Class II heart failure
AU2021900059 2021-01-12
AU2021902941 2021-09-10
AU2021902941A AU2021902941A0 (en) 2021-09-10 Method of treating progressive heart failure in subjects with Class II heart failure
AU2021903365A AU2021903365A0 (en) 2021-10-20 Method of treating progressive heart failure in subjects with Class II heart failure
AU2021903365 2021-10-20
US202163289868P 2021-12-15 2021-12-15
PCT/US2021/063645 WO2022132986A2 (en) 2020-12-15 2021-12-15 Method of treating progressive heart failure in subjects with class ii heart failure
US63/289,868 2021-12-15

Publications (2)

Publication Number Publication Date
JP2024500698A true JP2024500698A (ja) 2024-01-10
JP2024500698A5 JP2024500698A5 (enExample) 2024-12-25

Family

ID=79686821

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536167A Pending JP2024500698A (ja) 2020-12-15 2021-12-15 クラスｉｉ心不全を有する対象における進行性心不全を治療する方法

Country Status (6)

Country Link
US (1) US20240041934A1 (enExample)
JP (1) JP2024500698A (enExample)
KR (1) KR20230119676A (enExample)
AU (1) AU2021403025A1 (enExample)
CA (1) CA3202153A1 (enExample)
WO (1) WO2022132986A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4663241A3 (en) 2010-10-08 2026-03-25 Mesoblast International Sàrl Enhanced msc preparations
AU2018372631B2 (en) 2017-11-22 2025-06-05 Mesoblast International Sarl Cellular compositions and methods of treatment I

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US9205112B2 (en) * 2007-04-23 2015-12-08 Creative Medical Health, Inc. Combination treatment of cardiovascular disease
KR20240056789A (ko) * 2014-12-23 2024-04-30 메조블라스트 인터내셔널 에스에이알엘 진행성 심부전증의 예방
US20190224240A1 (en) * 2016-01-11 2019-07-25 Cardiocell, Llc Cell therapy for the treatment of non-ischemic heart failure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JORGE BARTOLUCCI ET AL.: "Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients", CIRCULATION RESEARCH, vol. 121, no. 10, JPN6025039345, 2017, pages 1192 - 1204, ISSN: 0005839059 *

Also Published As

Publication number Publication date
CA3202153A1 (en) 2022-06-23
US20240041934A1 (en) 2024-02-08
WO2022132986A2 (en) 2022-06-23
KR20230119676A (ko) 2023-08-16
AU2021403025A1 (en) 2023-07-20
WO2022132986A3 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
US20110091428A1 (en) Compositions of adult organ stem cells and uses thereof
KR20220143092A (ko) 만성 이식편 대 숙주 질환의 치료 방법
JP7315301B2 (ja) 進行性心不全の予防
US20240041934A1 (en) Method of treating progressive heart failure in subjects with class ii heart failure
CN115361958A (zh) 使用间充质谱系前体或干细胞治疗炎症性肺病的方法
US20240197787A1 (en) Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells
US20250032552A1 (en) Method of treating severe graft versus host disease
JP2025540289A (ja) 持続性炎症を有する対象における心不全の治療方法
JP2025540288A (ja) 細胞組成物を用いた炎症治療方法
US20250090589A1 (en) Method of treating progressive heart failure in subjects at high risk of poor outcomes
EP4433070A1 (en) Method of treating progressive heart failure in subjects at high risk of poor outcomes
CN116829162A (zh) 治疗患有ii级心力衰竭的受试者的进行性心力衰竭的方法
EP4264275A2 (en) Method of treating progressive heart failure in subjects with class ii heart failure
KR20260061190A (ko) GvHD에 대한 3차 치료
CN121985953A (zh) 用于治疗GvHD的三线治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260414